FDA: Uncomplicated Gonorrhea: Developing Drugs for Treatment

The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of uncomplicated gonorrhea. Specifically, this guidance addresses the Food and Drug Administration’s (FDA’s) current thinking regarding the overall development program and clinical trial designs for antibacterial drugs for the treatment of uncomplicated gonorrhea.